The biotech sector experiences significant regulatory and financial movements. FDA actions include accelerated approval of Boehringer’s pill for HER2-mutated lung cancer and scrutiny of rare disease drug reviews impacting company viability, notably Stealth Bio. Biopharma financing trends show a decline from 2024 but remain robust compared to prior post-pandemic lows, with notable fundraising by Frazier Life Sciences and Minghui Pharmaceutical. Corporate developments include biopharma M&A and emerging funding rounds supporting pipeline advancements.